BTIG maintains Buy rating on Haemonetics, $130 price target
BTIG kept a Buy rating on Haemonetics with a $130 price target, implying 27.8% upside. The firm cited a new CSL Plasma agreement and raised the valuation multiple to 21x, citing growth prospects and strong margins.
How this was made
The 30-second read
Why it matters
The rating upgrade could trigger buying interest and lift the stock toward the $130 target, especially in the near‑term trading session.
Market read
First‑time analyst upgrade with a concrete contract value, offering a clear short‑term catalyst for Haemonetics.
What to watch
Potential execution risk of transitioning all U.S. plasma centers to NexSys PCS devices.
Background
BTIG's research note provides a fresh analyst rating and price target for Haemonetics, a U.S.-listed medical‑device company.
Ticker impact
BTIG upgraded Haemonetics to Buy with a $130 price target, citing a new CSL Plasma supply agreement and raising the valuation multiple.
upward pressure as investors price in the rating upgrade and contract news
The upgrade is the first report of BTIG's new target and includes a concrete contract value, providing a clear catalyst for price appreciation.
Market effects
Positive for the blood‑collection and medical‑device sector as the CSL Plasma deal highlights demand for Haemonetics' PCS devices.
U.S. market may see modest buying pressure in healthcare equipment stocks.
Limited to investors tracking U.S. med‑tech equities.
Counterpoint
The upgrade may be premature if the CSL contract does not translate into sustained volume growth.
Key entities
- companyHaemonetics
U.S. medical‑device firm specializing in blood‑collection technology.
- companyCSL Plasma
Major plasma collection business entering a supply agreement with Haemonetics.
- analystBTIG
Equity research firm issuing the Buy rating and price target.
